ReviewInternational archives of allergy and immunology2017
Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy.
Review in International archives of allergy and immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Development of a novel Ara h 2 hypoallergen with no IgE binding or anaphylactogenic activity.The Journal of allergy and clinical immunology · 2020Trial
- A novel recognition of the major allergen, Hum j 1, fromThe World Allergy Organization journal · 2025Article
- From skin testing to molecular diagnostics: the precision leap in dust mite allergy diagnosis and clinical translation challenges.Frontiers in allergy · 2025Review
- Point-of-Care Fluorescence Biosensing System for Rapid Multi-Allergen Screening.Sensors (Basel, Switzerland) · 2024Article
- Insect Cell-Expressed Major Ragweed Allergen Amb a 1.01 Exhibits Similar Allergenic Properties to Its Natural Counterpart from Common Ragweed Pollen.International journal of molecular sciences · 2024Article
- Selected Technical Aspects of Molecular Allergy Diagnostics.Current issues in molecular biology · 2023Review
- New approaches to immunotherapy in house dust mite allergy.Clinical and experimental pediatrics · 2023Article
- Component-Resolved Diagnosis Based on a Recombinant Variant of Mus m 1 Lipocalin Allergen.International journal of molecular sciences · 2023Article
- Identification of carboxymethyl (CM)-binding proteins derived from Lolium multiflorum pollen extract and antibody reactivity in Brazilian allergic patients.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023Article
- Oligomerization and tyrosine nitration enhance the allergenic potential of the birch and grass pollen allergens Bet v 1 and Phl p 5.Frontiers in allergy · 2023Review
- Review
- pH-dependent structural diversity of profilin allergens determines thermal stability.Frontiers in allergy · 2022Article
- Hydrogen/deuterium exchange memory NMR reveals structural epitopes involved in IgE cross-reactivity of allergenic lipid transfer proteins.The Journal of biological chemistry · 2020Article
- Review
- Egg Allergy: Diagnosis and Immunotherapy.International journal of molecular sciences · 2020Review
- Bee Venom Immunotherapy: Current Status and Future Directions.Clinical reviews in allergy & immunology · 2020Review
- Conformational selection of allergen-antibody complexes-surface plasticity of paratopes and epitopes.Protein engineering, design & selection : PEDS · 2019Article
- Purification and Characterization of Pathogenesis Related Class 10 Panallergens.Foods (Basel, Switzerland) · 2019Article
- Review
- Structural Analysis of Recent Allergen-Antibody Complexes and Future Directions.Current allergy and asthma reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The years 1988-1995 witnessed the beginning of allergen cloning and the generation of recombinant allergens, which opened up new avenues for the diagnosis and research of human allergic diseases. Most crystal and solution structures of allergens have been obtained using recombinant allergens. Structural information on allergens allows insights into their evolutionary biology, illustrates clinically observed cross-reactivities, and makes the design of hypoallergenic derivatives for allergy vaccines possible. Recombinant allergens are widely used in molecule-based allergy diagnosis such as protein microarrays or suspension arrays. Recombinant technologies have been used to produce well-characterized, noncontaminated vaccine components with known biological activities including a variety of allergen derivatives with reduced IgE reactivity. Such recombinant hypoallergens as well as wild-type recombinant allergens have been used successfully in several immunotherapy trials for more than a decade to treat birch and grass pollen allergy. As a more recent application, the development of antibody repertoires directed against conformational epitopes during immunotherapy has been monitored by recombinant allergen chimeras. Although much progress has been made, the number and quality of recombinant allergens will undoubtedly increase and keep improving our knowledge in basic scientific investigations, diagnosis, and therapy of human allergic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.